Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.

Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, Pratt E, Kazda C, Konig M

The New England journal of medicine23 Jun 2023Cited by 360 (Europe PMC)

PMID37351564DOI10.1056/nejmoa2302392PepBankPUB-37351564

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity or overweight without diabetes, weight change ranged from -8.6% to -12.6% with orforglipron versus -2.0% with placebo.
In plain wordsIn adults with obesity or overweight without diabetes, orforglipron reduced weight more than placebo at week 26.
Peptide
Orforglipron
Outcome
DecreaseBody weight change at week 26
Study
n = 272
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
12, 24, 36, or 45 mg once daily · oral · 26 weeksAs given in this study (human).
Measurements
Weight change
−8.6 to −12.6%
orforglipron
Weight change
−2%
placebo
Source sentences
Summary
At week 26, the mean change from baseline in body weight ranged from -8.6% to -12.6% across the orforglipron dose cohorts and was -2.0% in the placebo group.
3 context sentences(design, population, supporting numbers)
Summary · context
The percentage change from baseline in body weight was assessed at week 26 (primary end point) and at week 36 (secondary end point).
Summary · context
In this phase 2, randomized, double-blind trial, we enrolled adults with obesity, or with overweight plus at least one weight-related coexisting condition, and without diabetes.
Summary · context
Participants were randomly assigned to receive orforglipron at one of four doses (12, 24, 36, or 45 mg) or placebo once daily for 36 weeks.
Report a problemFND-3735156401
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity or overweight without diabetes, weight change ranged from -9.4% to -14.7% with orforglipron versus -2.3% with placebo.
In plain wordsIn adults with obesity or overweight without diabetes, orforglipron reduced weight more than placebo at week 36.
Peptide
Orforglipron
Outcome
DecreaseBody weight change at week 36
Study
n = 272
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
12, 24, 36, or 45 mg once daily · oral · 36 weeksAs given in this study (human).
Measurements
Weight change
−9.4 to −14.7%
orforglipron
Weight change
−2.3%
placebo
Source sentences
Summary
At week 36, the mean change ranged from -9.4% to -14.7% with orforglipron and was -2.3% with placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
The percentage change from baseline in body weight was assessed at week 26 (primary end point) and at week 36 (secondary end point).
Summary · context
In this phase 2, randomized, double-blind trial, we enrolled adults with obesity, or with overweight plus at least one weight-related coexisting condition, and without diabetes.
Summary · context
Participants were randomly assigned to receive orforglipron at one of four doses (12, 24, 36, or 45 mg) or placebo once daily for 36 weeks.
Report a problemFND-3735156402
03HumanRandomized controlled trialEfficacy outcome
In adults with obesity or overweight without diabetes, at least 10% weight reduction occurred in 46 to 75% with orforglipron versus 9% with placebo.
In plain wordsIn adults with obesity or overweight without diabetes, more orforglipron recipients than placebo recipients lost at least 10% of weight.
Peptide
Orforglipron
Outcome
IncreaseAt least 10% weight reduction
Study
n = 272
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
12, 24, 36, or 45 mg once daily · oral · 36 weeksAs given in this study (human).
Measurements
Responder proportion
46 to 75%
orforglipron
Responder proportion
9%
placebo
Source sentences
Summary
A weight reduction of at least 10% by week 36 occurred in 46 to 75% of the participants who received orforglipron, as compared with 9% who received placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
In this phase 2, randomized, double-blind trial, we enrolled adults with obesity, or with overweight plus at least one weight-related coexisting condition, and without diabetes.
Summary · context
Participants were randomly assigned to receive orforglipron at one of four doses (12, 24, 36, or 45 mg) or placebo once daily for 36 weeks.
Report a problemFND-3735156403
04HumanRandomized controlled trialEfficacy outcome
In adults with obesity or overweight without diabetes, orforglipron improved all prespecified weight-related and cardiometabolic measures without individual outcomes reported.
In plain wordsIn adults with obesity or overweight without diabetes, orforglipron improved prespecified weight-related and cardiometabolic measures.
Peptide
Orforglipron
Outcome
Not applicablePrespecified weight-related and cardiometabolic measures
Study
n: not reported in source
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
12, 24, 36, or 45 mg once daily · oralAs given in this study (human).
Source sentences
Summary
The use of orforglipron led to improvement in all prespecified weight-related and cardiometabolic measures.
2 context sentences(design, population, supporting numbers)
Summary · context
In this phase 2, randomized, double-blind trial, we enrolled adults with obesity, or with overweight plus at least one weight-related coexisting condition, and without diabetes.
Summary · context
Participants were randomly assigned to receive orforglipron at one of four doses (12, 24, 36, or 45 mg) or placebo once daily for 36 weeks.
Report a problemFND-3735156404
05HumanRandomized controlled trialSafety outcome
In adults receiving orforglipron, gastrointestinal events were most common, mild to moderate, and occurred primarily during dose escalation.
In plain wordsIn adults receiving orforglipron, digestive adverse events were most common, mild to moderate, and occurred mainly during dose increases.
Peptide
Orforglipron
Outcome
Not applicableGastrointestinal adverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
12, 24, 36, or 45 mg once daily · oral · 36 weeksAs given in this study (human).
Source sentences
Summary
The most common adverse events reported with orforglipron were gastrointestinal events, which were mild to moderate, occurred primarily during dose escalation, and led to discontinuation of orforglipron in 10 to 17% of participants across dose cohorts.
2 context sentences(design, population, supporting numbers)
Summary · context
In this phase 2, randomized, double-blind trial, we enrolled adults with obesity, or with overweight plus at least one weight-related coexisting condition, and without diabetes.
Summary · context
Participants were randomly assigned to receive orforglipron at one of four doses (12, 24, 36, or 45 mg) or placebo once daily for 36 weeks.
Report a problemFND-3735156405
06HumanRandomized controlled trialSafety outcome
In adults receiving orforglipron, gastrointestinal events led to discontinuation in 10 to 17% across dose cohorts.
In plain wordsIn adults receiving orforglipron, digestive events caused 10 to 17% to stop treatment.
Peptide
Orforglipron
Outcome
Not applicableDiscontinuation due to gastrointestinal events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
12, 24, 36, or 45 mg once daily · oral · 36 weeksAs given in this study (human).
Measurements
Discontinuation proportion
10 to 17%
orforglipron dose cohorts
Source sentences
Summary
The most common adverse events reported with orforglipron were gastrointestinal events, which were mild to moderate, occurred primarily during dose escalation, and led to discontinuation of orforglipron in 10 to 17% of participants across dose cohorts.
2 context sentences(design, population, supporting numbers)
Summary · context
In this phase 2, randomized, double-blind trial, we enrolled adults with obesity, or with overweight plus at least one weight-related coexisting condition, and without diabetes.
Summary · context
Participants were randomly assigned to receive orforglipron at one of four doses (12, 24, 36, or 45 mg) or placebo once daily for 36 weeks.
Report a problemFND-3735156406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT05051579

A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities

Eli Lilly and Companyn = 27229 Sept 2021 to 22 Nov 2022

Obesity · Overweight and Obesity

Trial page ClinicalTrials.govUpdated 13 Sept 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.